Omeros (OMER) Total Non-Current Liabilities (2021 - 2026)
Omeros' (OMER) quarterly Total Non-Current Liabilities came in at $265.5 million in Q1 2026, down 40.24% year-on-year from $444.2 million in Q1 2025, and down 39.82% quarter-over-quarter from $441.2 million in Q4 2025.
Omeros (OMER) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends
Omeros has disclosed Total Non-Current Liabilities across 6 years of filings, most recently posting $265.5 million for Q1 2026.
- Total Non-Current Liabilities for Q1 2026 came in at $265.5 million, down 40.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $265.5 million (down 40.24% YoY), and the FY2025 annual result was $441.2 million, down 3.08% from the prior year.
- Total Non-Current Liabilities came in at $265.5 million for Q1 2026 at Omeros, down from $441.2 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $507.0 million in Q3 2023 to a low of $251.2 million in Q2 2025.
- The 5-year median for Total Non-Current Liabilities is $455.2 million (2024), against an average of $425.8 million.
- Across the five-year window, Total Non-Current Liabilities soared 35.22% in 2023 and slumped 47.54% in 2025, its largest moves.
- Omeros' Total Non-Current Liabilities stood at $504.8 million in 2022, then decreased by 20.54% to $401.2 million in 2023, then gained by 13.47% to $455.2 million in 2024, then declined by 3.08% to $441.2 million in 2025, then plunged by 39.82% to $265.5 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $265.5 million (Q1 2026), $441.2 million (Q4 2025), and $253.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 64.76 Mn |
| 10 | Omeros | 737.87 Mn | 602.55 Mn | 9.31 Mn | 265.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 265.48 Mn |
| Dec 31, 2025 | 441.16 Mn |
| Sep 30, 2025 | 253.66 Mn |
| Jun 30, 2025 | 251.17 Mn |
| Mar 31, 2025 | 444.21 Mn |
| Dec 31, 2024 | 455.19 Mn |
| Sep 30, 2024 | 464.41 Mn |
| Jun 30, 2024 | 478.82 Mn |
| Mar 31, 2024 | 506.73 Mn |
| Dec 31, 2023 | 401.16 Mn |
| Sep 30, 2023 | 507.02 Mn |
| Jun 30, 2023 | 506.42 Mn |
| Mar 31, 2023 | 504.74 Mn |
| Dec 31, 2022 | 504.84 Mn |
| Sep 30, 2022 | 502.87 Mn |
| Jun 30, 2022 | 377.38 Mn |
| Mar 31, 2022 | 373.27 Mn |
| Dec 31, 2021 | 394.37 Mn |